- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07558018
Evaluation of the Systemic Microcirculation as a Surrogate for Coronary Microcirculation in Women With ANOCA (NOCAWT)
May 2, 2026 updated by: Eduardo Tibirica, MD, PhD, National Institute of Cardiology, Laranjeiras, Brazil
Evaluation of the Systemic Microcirculation as a Surrogate for Coronary Microcirculation in Women With ANOCA: Insights Into Pathophysiology and Diagnosis Using Noninvasive, Innovative Techniques (NOCAWT)
The primary objective of this project is to validate a multi-modal systemic microvascular phenotyping platform-combining Laser Speckle Contrast Imaging (LSCI) and Sublingual Handheld Videomicroscopy (IDF imaging)-as a non-invasive surrogate for coronary microvascular function in women with ANOCA (Angina with Non-Obstructive Coronary Arteries).
We aim to demonstrate that systemic microvascular signatures (microvascular reactivity and density) can predict coronary endotypes with high accuracy, potentially reducing the need for invasive diagnostics.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will involve women aged 18 to 65 years, with stable anginal chest pain and no coronary artery disease (ANOCA) (absence of coronary plaque in coronary angiography or computed tomography coronary angiography - CCTA), recruited at the National Institute of Cardiology (INC).
The upper age limit was established to limit the influence of vascular senescence on the results.
Study Type
Observational
Enrollment (Estimated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Eduardo Tibirica, MD, PhD
- Phone Number: +55-21-99914-6075
- Email: etibi@uol.com.br
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Probability Sample
Study Population
Patients from a terciary cardiology hospital.
Description
Inclusion Criteria:
- Age 18-65 years
- Anginal chest pain
Exclusion Criteria:
- Malignant neoplasms
- Autoimmune diseases
- Acute systemic diseases
- Pregnancy or lactation
- Iodine allergy
- CAD on invasive coronary angiography or coronary computed tomography angiography (CCTA)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
ANOCA
Symptomatic Group (ANOCA): n = 40 patients with stable angina and non-obstructive coronary arteries.
|
Investigation of Systemic Endothelial Microvascular Function
Other Names:
|
|
CONTROL
Control Group: n = 20 age-matched women without chest pain and without CAD.
|
Investigation of Systemic Endothelial Microvascular Function
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of endothelium-dependent skin microvascular reactivity.
Time Frame: Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.
|
Evaluation of systemic microvascular reactivity induced by endothelium-dependent agent (acetylcholine).
Microvascular reactivity will be evaluated using a non-invasive and operator -independent methodology, named laser speckle contrast imaging, coupled with skin iontophoresis of vasodilator agents.
Cutaneous microvascular flow will be measured in arbitrary perfusion units, divided by mean arterial pressure, to yield cutaneous vascular conductance.
|
Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of endothelium-independent skin microvascular reactivity.
Time Frame: Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.
|
Evaluation of systemic microvascular reactivity induced by endothelium-independent agent (sodium nitroprusside).
Microvascular reactivity will be evaluated using a non-invasive and operator -independent methodology, named laser speckle contrast imaging, coupled with skin iontophoresis of vasodilator agents.
Cutaneous microvascular flow will be measured in arbitrary perfusion units, divided by mean arterial pressure, to yield cutaneous vascular conductance.
|
Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.
|
|
Evaluation of endothelium-dependent skin microvascular reactivity.
Time Frame: Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.
|
Evaluation of systemic microvascular reactivity induced by postocclusive reactive hyperemia.
Microvascular reactivity will be evaluated using a non-invasive and operator -independent methodology, named laser speckle contrast imaging.
Cutaneous microvascular flow will be measured in arbitrary perfusion units, divided by mean arterial pressure, to yield cutaneous vascular conductance.
|
Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.
|
|
Evaluation of sublingual microcirculation.
Time Frame: Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.
|
Sublingual microcirculatory density and perfusion will be assessed using a handheld camera based on incident dark-field (IDF) imaging.
|
Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2026
Primary Completion (Estimated)
December 1, 2029
Study Completion (Estimated)
December 1, 2029
Study Registration Dates
First Submitted
April 22, 2026
First Submitted That Met QC Criteria
April 22, 2026
First Posted (Actual)
April 30, 2026
Study Record Updates
Last Update Posted (Actual)
May 5, 2026
Last Update Submitted That Met QC Criteria
May 2, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NOCoronaryArtery Women Testing
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angina, Microvascular
-
Medstar Health Research InstituteRecruiting
-
VahatiCor, Inc.RecruitingCoronary Microvascular Disease | Coronary Microvascular DysfunctionSpain, Netherlands, Poland
-
Institute for Cardiovascular Diseases "Dedinje"Abbott Medical DevicesRecruitingCoronary Artery Disease | Coronary Microvascular Dysfunction | Angina, MicrovascularSerbia, Greece, Croatia, Israel, Slovenia
-
China-Japan Friendship HospitalRecruitingCoronary Microvascular Angina | MacitentanChina
-
Spanish Society of CardiologyRecruitingAngina, Stable | Coronary Microvascular Disease | Coronary Microvascular DysfunctionSpain
-
Qilu Hospital of Shandong UniversityNot yet recruitingDiabetic Microvascular AnginaChina
-
Royal United Hospitals Bath NHS Foundation TrustNational Institute for Health Research, United KingdomRecruitingMicrovascular Angina | Coronary Microvascular Dysfunction (CMD) | Microvascular Coronary DysfunctionUnited Kingdom
-
Johannes Gutenberg University MainzNeovasc Inc.RecruitingRefractory Angina | Coronary Microvascular DiseaseGermany
-
Qilu Hospital of Shandong UniversityRecruitingCoronary Microvascular DiseaseChina
-
Peking University First HospitalRecruiting
Clinical Trials on Investigation of Systemic Endothelial Microvascular Function
-
National Institute of Cardiology, Laranjeiras,...CompletedObesity | DyslipidemiasBrazil
-
National Institute of Cardiology, Laranjeiras,...CompletedEndothelial Dysfunction | Arterial Hypertension | Resistant Hypertension | Microvascular RarefactionBrazil
-
National Institute of Cardiology, Laranjeiras,...CompletedMyocardial IschemiaBrazil
-
National Institute of Cardiology, Laranjeiras,...Enrolling by invitationResistant Arterial HypertensionBrazil
-
Johannes Gutenberg University MainzRecruiting
-
Centre Hospitalier Universitaire, AmiensCompletedAortic Valve Disease | Endothelial DysfunctionFrance
-
Losordo, Douglas, M.D.WithdrawnIschemic Congestive Heart Failure (CHF)
-
University Hospital, Clermont-FerrandCompleted
-
I.M. Sechenov First Moscow State Medical UniversityCompletedCardiotoxicityRussian Federation
-
RWTH Aachen UniversityDFG - Deutsche Forschungs Gemeinschaft (German Research Foundation)RecruitingCOPD | Sympathetic Nervous System Diseases | Catecholamine; OverproductionGermany